Cardioprotective effects of atorvastatin plus trimetazidine in percutaneous coronary intervention

Abstract

Objective: To explore the effects of preoperative administration of conventional doses of atorvastatin plus trimetazidine on the myocardial injury of patients during the perioperative period of percutaneous coronary intervention (PCI). Methodology: 475 cases of acute coronary syndrome patients before PCI were randomly divided into the control group (238 cases) and experimental group (237 cases).The control group was treated with conventional doses of atorvastatin calcium (20 mg each time, once a night), and the experimental group was treated with conventional doses of atorvastatin calcium plus trimetazidine hydrochloride (20 mg each time, tid) for 3 d. After PCI, preoperative and postoperative 24 h concentrations of serum creatine kinase MB isoenzyme (CK-MB), cardiac troponin I (cTnI) and high sensitivity C-reactive protein (hs-CRP) as well as activity of myeloperoxidase (MPO) were investigated. Left ventricular ejection fractions of the patients were then examined 4 weeks later. Results: Postoperative 24 h cTnI concentration and elevated MPO activity of the experimental group were significantly lower than those of the control group (P <0 05). CK-MB activities and hs-CRP concentrations of the two groups did not differ significantly (P> 0 05). Conclusion: The administration of conventional doses of atorvastatin plus trimetazidine three days before PCI is able to protect the perioperative patients from myocardial injury.

Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention–induced myocardial injury

“…Combination TMZ therapy with high-dose atorvastatin has also been reported to lower post-PCI biomarkers including cTnI, myeloperoxidase high-sensitivity C-reactive protein, tumor necrosis factor-α, and serum interferon-γ levels 32, 33…”

Myocardial Cytoprotector Trimetazidine Mb-Preparat, Increases the Effectiveness of Treatment of Chronic Heart Failure and Coronary Heart Disease

“…При хирурги-ческом лечении ИБС триметазидин МВ предотвращал поражение миокарда во время ишемии и реперфузии [62], а в пред-и послеоперационных периодах при при-еме препарата отмечали улучшение общей и локальной сократимости ЛЖ [63]. Триметазидин в сочетании с обыч-ными дозами аторвастатина за 3 дня до ЧКВ эффективно защищает пациентов в послеоперационном периоде от повреждения миокарда [64]. Приме нение триметазидина в течение 1 месяца после имплантации стентов с лекар-ственным покрытием (DES) эффек тивно снижает в тече-ние однолетнего наблюдения за пациентами частоту рестеноза стента и неблагоприятных сердечных и цере-броваскулярных событий [65].…”

Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization

“…The combination therapy based on ATOR and TMZ could provide an effective improvement on cardiac functions; reduces the level of inflammatory factors and improves the endothelial function in patients with coronary heart disease which greatly reduce the risk of myocardial injury and enhance cure rates (Tian, 2016, Lin et al, 2013). Hence, combining both ATOR and TMZ into a single formulation will be beneficial for patients with coronary heart disease and can minimize the prevalence of postoperative myocardial injury as well as effectively improve their lipid profile (Song and Wang, 2018, Wang et al, 2018, Xu et al, 2017).…”